[Federal Register Volume 88, Number 158 (Thursday, August 17, 2023)]
[Notices]
[Pages 56027-56028]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-17672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Collaboration Opportunity To Develop a Vaccine Against Nicotine 
or Arecoline

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Cancer Prevention Program of the National Cancer Institute 
(NCI) is seeking a partner in the private

[[Page 56028]]

sector to develop a vaccine directed against nicotine or a related 
molecule called arecoline, with the goal of reducing or eliminating the 
craving of such substance(s) in smokers or betel nut users.

FOR FURTHER INFORMATION CONTACT: Inquiries relating to this 
collaboration opportunity should be directed to: Michael Pollack, 
Ph.D., Supervisory Technology Transfer Manager, NCI Technology Transfer 
Center, 9609 Medical Center Drive, Room 1E530, Rockville, MD 20850 (for 
overnight mail) or Bethesda, MD 20892 (for regular mail), Telephone: 
(240) 276-5530; Facsimile: (240) 276-5504; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The NCI has expertise in the latest 
technology of vaccine development and agents to enhance immune 
responses to vaccines, and NCI has the ability to participate in 
vaccine preclinical and clinical studies. The NCI is seeking a partner 
with expertise in this area of anti-smoking research and development.

    Dated: August 11, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2023-17672 Filed 8-16-23; 8:45 am]
BILLING CODE 4140-01-P